S49 Analyst Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
S49 Stock 12 Month Forecast
Average Price Target
―| Highest Price TargetCHF54.61 | Average Price TargetCHF51.30 | Lowest Price TargetCHF45.51 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bank of America Securities
CHF49.65→CHF45.51
Buy
―
Reiterated
10/15/26
TD Cowen
CHF53.78
Buy
―
Reiterated
08/03/26
Piper Sandler
CHF54.61
Buy
―
Reiterated
07/27/26
Cantor Fitzgerald
CHF52.13→CHF55.44
Buy
―
Reiterated
07/09/26
Stifel Nicolaus
CHF45.51
Hold
―
Reiterated
05/06/26
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bank of America Securities
CHF49.65→CHF45.51
Buy
―
Reiterated
10/15/26
TD Cowen
CHF53.78
Buy
―
Reiterated
08/03/26
Piper Sandler
CHF54.61
Buy
―
Reiterated
07/27/26
Cantor Fitzgerald
CHF52.13→CHF55.44
Buy
―
Reiterated
07/09/26
Stifel Nicolaus
CHF45.51
Hold
―
Reiterated
05/06/26
Best Analysts Covering Supernus Pharmaceuticals
3 Months
Success Rate
13/27 ratings generated profit
Average Return
-0.20%
Copying David Amsellem's trades and holding each position for 3 Months would result in 48.15% of your transactions generating a profit, with an average return of -0.20% per trade.
1 Year
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
S49 Analyst Recommendation Trends
Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
0
0
0
Buy
6
7
6
5
3
Hold
1
1
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
8
6
5
3
Each month's total comprises the sum of three months' worth of ratings.
S49 Financial Forecast
S49 Stock Forecast FAQ
What is CH:S49’s average 12-month price target, according to analysts?
Based on analyst ratings, Supernus Pharmaceuticals’s 12-month average price target is 51.30.
What is CH:S49’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for CH:S49, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Supernus Pharmaceuticals a Buy, Sell or Hold?
Supernus Pharmaceuticals has a consensus rating of Strong Buy, which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
What is Supernus Pharmaceuticals’s share price target?
The average share price target for Supernus Pharmaceuticals is 51.30. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF54.61 ,and the lowest forecast is CHF45.51. The average share price target represents N/A Increase from the current price of N/A.
The highest analyst share price target is CHF54.61 ,and the lowest forecast is CHF45.51. The average share price target represents N/A Increase from the current price of N/A.
What do analysts say about Supernus Pharmaceuticals?
Supernus Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of Supernus Pharmaceuticals?
To buy shares of CH:S49, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.